Table 2 Overall responses in patients receiving S-1 plus cisplatin or cisplatin alone

From: Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer

 

Study group (n = 169)

Control group (n = 149)

P valuea

Best overall response, n (%)

  

NA

 Complete response

21 (12.4)

6 (4.0)

 

 Partial response

53 (31.4)

24 (16.1)

 

 Stable disease

54 (32.0)

54 (36.2)

 

 Progressive disease

24 (14.2)

43 (28.9)

 

 Unknownb

17 (10.1)

22 (14.8)

 

Overall response rate, n (%)

74 (43.8)

30 (20.1)

<0.001

95% CI

36.2–51.6%

14.0–27.5%

Disease control rate (CR + PR + SD), n (%)

128 (75.7)

84 (56.4)

<0.001

95% CI

68.6–82.0%

48.0–64.5%

  1. The overall response rate-evaluable population was used. Study group, S-1 plus cisplatin; Control group, cisplatin.
  2. CI confidence interval, CR complete response, NA not applicable, PR partial response, SD stable disease.
  3. aP value was calculated using Fisher’s exact test.
  4. bUnknown contains ‘not assessable’ or ‘insufficient data’
Back to article page